

BENCHMARKS FOR MEASURES INCLUDED IN THE PERFORMANCE YEAR 2014 QUALITY AND RESOURCE USE REPORTS

CMS-Calculated Outcome Measures

PQRS Measure Number and Measure Name		2013 Mean	2013 Standard Deviation
CMS-1	Acute Conditions Composite*	7.53	5.72
	<i>Bacterial Pneumonia*</i>	11.20	9.43
	<i>Urinary Tract Infection*</i>	7.25	7.84
	<i>Dehydration*</i>	4.10	4.49
CMS-2	Chronic Conditions Composite*	50.43	24.23
	<i>Diabetes (composite of 4 indicators)*</i>	18.07	20.00
	<i>COPD or Asthma*</i>	70.23	44.80
	<i>Heart Failure*</i>	99.75	51.03
CMS-3	All-Cause Hospital Readmissions	15.94%	1.39%

Note: Lower performance rates on these measures indicate better performance.

* Rate per 1,000 beneficiaries

Physician Quality Reporting System (PQRS) Measures

2013 PQRS Measure Number and Measure Name		2013 Mean	2013 Standard Deviation	2013 Reporting Options				
				Claims	Registry	EHR	Measures Group	GPRO Web Interface
Clinical Process/Effectiveness								
1* (GPRO DM-2)	Diabetes Mellitus (DM): Hemoglobin A1c Poor Control	20.49%	18.64%	X	X	X	X	X
2	Diabetes Mellitus (DM): Low Density Lipoprotein (LDL-C) Control	52.81%	20.86%	X	X	X	X	-
3	Diabetes Mellitus (DM): High Blood Pressure Control	72.43%	17.04%	X	X	X	X	-
5	Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD)	77.33%	25.82%	-	X	X	X	-
6	Coronary Artery Disease (CAD): Antiplatelet Therapy	83.89%	20.35%	X	X	X	X	-
7	Coronary Artery Disease (CAD): Beta-Blocker Therapy—Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVSD) (LVEF < 40%)	66.92%	23.57%	-	X	X	-	-
8 (GPRO HF-6)	Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)	80.50%	22.49%	-	X	X	X	X
9	Major Depressive Disorder (MDD): Antidepressant Medication During Acute Phase for Patients with MDD	42.01%	29.21%	X	X	X	-	-
12	Primary Open-Angle Glaucoma (POAG): Optic Nerve Evaluation	96.63%	8.71%	X	X	X	-	-
14	Age-Related Macular Degeneration (AMD): Dilated Macular Examination	95.61%	15.83%	X	X	-	-	-
18	Diabetic Retinopathy: Documentation of Presence or Absence of Macular Edema and Level of Severity of Retinopathy	96.48%	12.46%	X	X	X	-	-
19	Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care	91.58%	21.02%	X	X	X	-	-
28	Aspirin at Arrival for Acute Myocardial Infarction (AMI)	87.43%	10.52%	X	X	-	-	-

2013 PQRS Measure Number and Measure Name		2013 Mean	2013 Standard Deviation	2013 Reporting Options				
				Claims	Registry	EHR	Measures Group	GPRO Web Interface
31	Stroke and Stroke Rehabilitation: Deep Vein Thrombosis (DVT) Prophylaxis for Ischemic Stroke or Intracranial Hemorrhage	84.42%	14.50%	X	X	-	-	-
32	Stroke and Stroke Rehabilitation: Discharged on Antithrombotic Therapy	90.45%	11.44%	X	X	-	-	-
33	Stroke and Stroke Rehabilitation: Anticoagulant Therapy Prescribed for Atrial Fibrillation (AF) at Discharge	-	-	-	X	-	-	-
35	Stroke and Stroke Rehabilitation: Screening for Dysphagia	93.04%	14.30%	X	X	-	-	-
36	Stroke and Stroke Rehabilitation: Rehabilitation Services Ordered	87.45%	13.35%	X	X	-	-	-
39	Screening or Therapy for Osteoporosis for Women Aged 65 Years and Older	35.02%	30.20%	X	X	X	X	-
40	Osteoporosis: Management Following Fracture of Hip, Spine or Distal Radius for Men and Women Aged 50 Years and Older	-	-	X	X	-	-	-
41	Osteoporosis: Pharmacologic Therapy for Men and Women Aged 50 Years and Older	69.53%	28.57%	X	X	-	-	-
43	Coronary Artery Bypass Graft (CABG): Use of Internal Mammary Artery (IMA) in Patients with Isolated CABG Surgery	99.00%	2.46%	X	X	-	X	-
44	Coronary Artery Bypass Graft (CABG): Preoperative Beta-Blocker in Patients with Isolated CABG Surgery	97.04%	5.77%	X	X	-	X	-
48	Urinary Incontinence: Assessment of Presence or Absence of Urinary Incontinence in Women Aged 65 Years and Older	75.01%	36.78%	X	X	X	X	-
49	Urinary Incontinence: Characterization of Urinary Incontinence in Women Aged 65 Years and Older	96.76%	8.87%	X	X	-	-	-
51	Chronic Obstructive Pulmonary Disease (COPD): Spirometry Evaluation	84.18%	21.91%	X	X	-	X	-
52	Chronic Obstructive Pulmonary Disease (COPD): Bronchodilator Therapy	89.98%	24.43%	X	X	-	X	-

2013 PQRS Measure Number and Measure Name	2013 Mean	2013 Standard Deviation	2013 Reporting Options					
			Claims	Registry	EHR	Measures Group	GPRO Web Interface	
53	Asthma: Pharmacologic Therapy for Persistent Asthma—Ambulatory Care Setting	-	-	X	X	X	X	-
54	Emergency Medicine: 12-Lead Electrocardiogram (ECG) Performed for Non-Traumatic Chest Pain	96.93%	3.74%	X	X	-	-	-
55	Emergency Medicine: 12-Lead Electrocardiogram (ECG) Performed for Syncope	96.62%	8.06%	X	X	-	-	-
56	Emergency Medicine: Community-Acquired Pneumonia (CAP): Vital Signs	97.53%	6.52%	X	X	-	-	-
59	Emergency Medicine: Community-Acquired Pneumonia (CAP): Empiric Antibiotic	95.26%	7.28%	X	X	-	-	-
64	Asthma: Assessment of Asthma Control—Ambulatory Care Setting	-	-	X	X	X	X	-
67	Hematology: Myelodysplastic Syndrome (MDS) and Acute Leukemias: Baseline Cytogenetic Testing Performed on Bone Marrow	96.06%	7.81%	X	X	-	-	-
68	Hematology: Myelodysplastic Syndrome (MDS): Documentation of Iron Stores in Patients Receiving Erythropoietin Therapy	93.58%	17.86%	X	X	-	-	-
69	Hematology: Multiple Myeloma: Treatment with Bisphosphonates	88.62%	15.13%	X	X	-	-	-
70	Hematology: Chronic Lymphocytic Leukemia (CLL): Baseline Flow Cytometry	96.39%	8.09%	X	X	-	-	-
71	Breast Cancer: Hormonal Therapy for Stage IC—IIIC Estrogen Receptor/Progesterone Receptor (ER/PR) Positive Breast Cancer	97.34%	6.88%	X	X	X	X	-
72	Colon Cancer: Chemotherapy for AJCC Stage III Colon Cancer Patients	98.37%	3.61%	X	X	X	X	-
83	Hepatitis C: Testing for Chronic Hepatitis C—Confirmation of Hepatitis C Viremia	-	-	-	X	-	-	-

2013 PQRS Measure Number and Measure Name	2013 Mean	2013 Standard Deviation	2013 Reporting Options					
			Claims	Registry	EHR	Measures Group	GPRO Web Interface	
84	Hepatitis C: Ribonucleic Acid (RNA) Testing Before Initiating Treatment	-	-	X	X	-	X	-
85	Hepatitis C: Hepatitis C Virus (HCV) Genotype Testing Prior to Treatment	-	-	X	X	-	X	-
86	Hepatitis C: Antiviral Treatment Prescribed	-	-	X	X	-	X	-
87	Hepatitis C: Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Testing at Week 12 of Treatment	-	-	X	X	-	X	-
89	Hepatitis C: Counseling Regarding Risk of Alcohol Consumption	75.11%	21.19%	X	X	-	X	-
90	Hepatitis C: Counseling Regarding Use of Contraception Prior to Antiviral Therapy	-	-	X	X	-	X	-
91	Acute Otitis Externa (AOE): Topical Therapy	92.11%	14.70%	X	X	-	-	-
99	Breast Cancer Resection Pathology Reporting: pT Category (Primary Tumor) and pN Category (Regional Lymph Nodes) with Histologic Grade	97.13%	11.28%	X	X	-	-	-
100	Colorectal Cancer Resection Pathology Reporting: pT Category (Primary Tumor) and pN Category (Regional Lymph Nodes) with Histologic Grade	98.57%	3.40%	X	X	-	-	-
104	Prostate Cancer: Adjuvant Hormonal Therapy for High Risk Prostate Cancer Patients	81.51%	28.73%	X	X	-	-	-
106	Adult Major Depressive Disorder (MDD): Comprehensive Depression Evaluation: Diagnosis and Severity	81.29%	32.87%	X	X	-	-	-
107	Adult Major Depressive Disorder (MDD): Suicide Risk Assessment	75.57%	34.97%	X	X	-	-	-
108	Rheumatoid Arthritis (RA): Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy	92.78%	17.34%	X	X	-	X	-
111 (GPRO PREV-8)	Preventive Care and Screening: Pneumococcal Vaccination for Patients 65 Years and Older	45.42%	31.01%	X	X	X	X	X

2013 PQRS Measure Number and Measure Name		2013 Mean	2013 Standard Deviation	2013 Reporting Options				
				Claims	Registry	EHR	Measures Group	GPRO Web Interface
112 (GPRO PREV-5)	Preventive Care and Screening: Breast Cancer Screening for Women Aged 40-69	46.33%	27.47%	X	X	X	X	X
113 (GPRO PREV-6)	Preventive Care and Screening: Colorectal Cancer Screening	46.48%	30.68%	X	X	X	X	X
117	Diabetes Mellitus (DM): Dilated Eye Exam	87.50%	25.59%	X	X	X	X	-
118 (GPRO CAD-7)	Coronary Artery Disease (CAD): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy—Diabetes or Left Ventricular Systolic Dysfunction (LVSD) (LVEF < 40%)	66.64%	23.63%	-	X	-	-	X
119	Diabetes Mellitus (DM): Medical Attention for Nephropathy	80.93%	17.64%	X	X	X	X	-
121	Adult Kidney Disease: Laboratory Testing (Lipid Profile)	55.71%	30.13%	X	X	-	X	-
122	Adult Kidney Disease: Blood Pressure Management	56.53%	21.86%	X	X	-	X	-
123*	Adult Kidney Disease: Patients On Erythropoiesis-Stimulating Agent (ESA)—Hemoglobin Level > 12.0 g/dL	9.93%	19.31%	X	X	-	X	-
126	Diabetes Mellitus (DM): Diabetic Foot and Ankle Care, Peripheral Neuropathy—Neurological Evaluation	86.66%	28.24%	X	X	-	-	-
127	Diabetes Mellitus (DM): Diabetic Foot and Ankle Care, Ulcer Prevention—Evaluation of Footwear	89.43%	23.76%	X	X	-	-	-
137	Melanoma: Continuity of Care—Recall System	97.81%	10.20%	-	X	-	-	-
140	Age-Related Macular Degeneration (AMD): Counseling on Antioxidant Supplement	92.41%	18.95%	X	X	-	-	-
142	Osteoarthritis (OA): Assessment for Use of Anti-Inflammatory or Analgesic Over-the-Counter (OTC) Medications	75.44%	22.53%	X	X	-	-	-
149	Back Pain: Physical Exam	91.79%	23.07%	-	-	-	X	-
150	Back Pain: Advice for Normal Activities	83.78%	29.13%	-	-	-	X	-
151	Back Pain: Advice Against Bed Rest	81.08%	31.32%	-	-	-	X	-
159	HIV/AIDS: CD4+ Cell Count or CD4+ Percentage	93.90%	6.89%	-	X	-	X	-

2013 PQRS Measure Number and Measure Name		2013 Mean	2013 Standard Deviation	2013 Reporting Options				
				Claims	Registry	EHR	Measures Group	GPRO Web Interface
160	HIV/AIDS: Pneumocystis Jiroveci Pneumonia (PCP) Prophylaxis	-	-	-	X	-	X	-
161	HIV/AIDS: Adolescent and Adult Patients with HIV/AIDS Who Are Prescribed Potent Antiretroviral Therapy	97.54%	8.78%	-	X	-	X	-
162	HIV/AIDS: HIV RNA Control After Six Months of Potent Antiretroviral Therapy	98.09%	3.21%	-	X	-	X	-
163	Diabetes Mellitus (DM): Foot Exam	65.65%	34.71%	X	X	X	X	-
164*	Coronary Artery Bypass Graft (CABG): Prolonged Intubation	-	-	-	X	-	X	-
165*	Coronary Artery Bypass Graft (CABG): Deep Sternal Wound Infection Rate	-	-	-	X	-	X	-
166*	Coronary Artery Bypass Graft (CABG): Stroke	-	-	-	X	-	X	-
167*	Coronary Artery Bypass Graft (CABG): Postoperative Renal Failure	-	-	-	X	-	X	-
168*	Coronary Artery Bypass Graft (CABG): Surgical Re-Exploration	-	-	-	X	-	X	-
169	Coronary Artery Bypass Graft (CABG): Antiplatelet Medications at Discharge	-	-	-	X	-	X	-
170	Coronary Artery Bypass Graft (CABG): Beta-Blockers Administered at Discharge	-	-	-	X	-	X	-
171	Coronary Artery Bypass Graft (CABG): Anti-Lipid Treatment at Discharge	-	-	-	X	-	X	-
172	Hemodialysis Vascular Access Decision-Making by Surgeon to Maximize Placement of Autogenous Arterial Venous (AV) Fistula	96.78%	7.62%	X	X	-	-	-
176	Rheumatoid Arthritis (RA): Tuberculosis Screening	96.95%	9.50%	X	X	-	X	-
177	Rheumatoid Arthritis (RA): Periodic Assessment of Disease Activity	96.87%	11.82%	X	X	-	X	-
178	Rheumatoid Arthritis (RA): Functional Status Assessment	92.74%	19.24%	X	X	-	X	-

2013 PQRS Measure Number and Measure Name		2013 Mean	2013 Standard Deviation	2013 Reporting Options				
				Claims	Registry	EHR	Measures Group	GPRO Web Interface
179	Rheumatoid Arthritis (RA): Assessment and Classification of Disease Prognosis	92.16%	19.54%	X	X	-	X	-
187	Stroke and Stroke Rehabilitation: Thrombolytic Therapy	-	-	-	X	-	-	-
191	Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery	95.81%	5.92%	-	X	-	X	-
194	Oncology: Cancer Stage Documented	90.19%	18.58%	X	X	-	X	-
195	Radiology: Stenosis Measurement in Carotid Imaging Reports	81.49%	20.75%	X	X	-	-	-
197 (GPRO CAD-2)	Coronary Artery Disease (CAD): Lipid Control	53.13%	26.64%	-	X	X	X	X
198	Heart Failure (HF): Left Ventricular Ejection Fraction (LVEF) Assessment	72.04%	32.06%	-	X	-	X	-
200	Heart Failure (HF): Warfarin Therapy for Patients with Atrial Fibrillation	45.34%	10.19%	-	-	X	-	-
201	Ischemic Vascular Disease (IVD): Blood Pressure Management	73.13%	17.92%	X	X	X	X	-
204 (GPRO IVD-2)	Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antithrombotic	70.56%	24.44%	X	X	X	X	X
205	HIV/AIDS: Sexually Transmitted Disease Screening for Chlamydia and Gonorrhea	53.32%	35.00%	-	X	-	X	-
208	HIV/AIDS: Sexually Transmitted Disease Screening for Syphilis	73.32%	27.81%	-	X	-	X	-
209	Functional Communication Measure—Spoken Language Comprehension for Patients with Diagnosis of Late Effects of Cerebrovascular Disease (CVD)	-	-	-	X	-	-	-
210	Functional Communication Measure—Attention for Patients with Diagnosis of Late Effects of Cerebrovascular Disease (CVD)	-	-	-	X	-	-	-

2013 PQRS Measure Number and Measure Name		2013 Mean	2013 Standard Deviation	2013 Reporting Options				
				Claims	Registry	EHR	Measures Group	GPRO Web Interface
211	Functional Communication Measure—Memory for Patients with Diagnosis of Late Effects of Cerebrovascular Disease (CVD)	-	-	-	X	-	-	-
212	Functional Communication Measure—Motor Speech for Patients with Diagnosis of Late Effects of Cerebrovascular Disease (CVD)	-	-	-	X	-	-	-
213	Functional Communication Measure—Reading for Patients with Diagnosis of Late Effects of Cerebrovascular Disease (CVD)	-	-	-	X	-	-	-
214	Functional Communication Measure—Spoken Language Expression for Patients with Diagnosis of Late Effects of Cerebrovascular Disease (CVD)	-	-	-	X	-	-	-
215	Functional Communication Measure—Writing for Patients with Diagnosis of Late Effects of Cerebrovascular Disease (CVD)	-	-	-	X	-	-	-
216	Functional Communication Measure—Swallowing for Patients with Diagnosis of Late Effects of Cerebrovascular Disease (CVD)	-	-	-	X	-	-	-
228	Heart Failure (HF): Left Ventricular Function (LVF) Testing	51.15%	35.83%	-	X	-	-	-
231	Asthma: Tobacco Use: Screening—Ambulatory Care Setting	97.14%	10.67%	X	X	-	X	-
232	Asthma: Tobacco Use: Intervention—Ambulatory Care Setting	-	-	X	X	-	X	-
233	Thoracic Surgery: Recording of Performance Status Prior to Lung or Esophageal Cancer Resection	-	-	-	X	-	-	-
236 (GPRO HTN-2)	Hypertension (HTN): Controlling High Blood Pressure	73.99%	19.23%	X	X	X	X	X
237	Hypertension (HTN): Blood Pressure Measurement	98.59%	5.95%	-	-	X	-	-
241 (GPRO IVD-1)	Ischemic Vascular Disease (IVD): Complete Lipid Panel and Low Density Lipoprotein (LDL-C) Control	47.14%	23.12%	X	X	X	X	X

2013 PQRS Measure Number and Measure Name		2013 Mean	2013 Standard Deviation	2013 Reporting Options				
				Claims	Registry	EHR	Measures Group	GPRO Web Interface
242	Coronary Artery Disease (CAD): Symptom Management	88.40%	20.53%	-	X	-	X	-
243	Cardiac Rehabilitation Patient Referral from an Outpatient Setting	-	-	-	X	-	-	-
244	Hypertension (HTN): Blood Pressure Management	66.58%	15.02%	-	X	-	-	-
245	Chronic Wound Care: Use of Wound Surface Culture Technique in Patients with Chronic Skin Ulcers (Overuse Measure)	99.94%	0.51%	X	X	-	-	-
246	Chronic Wound Care: Use of Wet to Dry Dressings in Patients with Chronic Skin Ulcers (Overuse Measure)	99.54%	3.14%	X	X	-	-	-
247	Substance Use Disorders: Counseling Regarding Psychosocial and Pharmacologic Treatment Options for Alcohol Dependence	-	-	X	X	-	-	-
248	Substance Use Disorders: Screening for Depression Among Patients with Substance Abuse or Dependence	-	-	X	X	-	-	-
249	Barrett's Esophagus	99.30%	4.35%	X	X	-	-	-
250	Radical Prostatectomy Pathology Reporting	99.19%	3.98%	X	X	-	-	-
251	Immunohistochemical (IHC) Evaluation of Human Epidermal Growth Factor Receptor 2 Testing (HER2) for Breast Cancer Patients	99.56%	3.76%	X	X	-	-	-
252	Anticoagulation for Acute Pulmonary Embolus Patients	93.77%	6.45%	X	X	-	-	-
254	Ultrasound Determination of Pregnancy Location for Pregnant Patients with Abdominal Pain	-	-	X	X	-	-	-
255	Rh Immunoglobulin (Rhogam) for Rh-Negative Pregnant Women at Risk of Fetal Blood Exposure	-	-	X	X	-	-	-
257	Statin Therapy at Discharge after Lower Extremity Bypass (LEB)	-	-	-	X	-	-	-
263	Preoperative Diagnosis of Breast Cancer	96.73%	11.64%	X	X	-	-	-
264	Sentinel Lymph Node Biopsy for Invasive Breast Cancer	94.72%	6.39%		X	-	-	-

2013 PQRS Measure Number and Measure Name	2013 Mean	2013 Standard Deviation	2013 Reporting Options					
			Claims	Registry	EHR	Measures Group	GPRO Web Interface	
266	Epilepsy: Seizure Type(s) and Current Seizure Frequency(ies)	97.38%	6.96%	X	X	-	-	-
267	Epilepsy: Documentation of Etiology of Epilepsy or Epilepsy Syndrome	96.46%	9.88%	X	X	-	-	-
268	Epilepsy: Counseling for Women of Childbearing Potential with Epilepsy	-	-	X	X	-	-	-
269	Inflammatory Bowel Disease (IBD): Type, Anatomic Location and Activity All Documented	90.26%	15.54%	-	-	-	X	-
270	Inflammatory Bowel Disease (IBD): Preventive Care: Corticosteroid Sparing Therapy	-	-	-	-	-	X	-
271	Inflammatory Bowel Disease (IBD): Preventive Care: Corticosteroid Related Iatrogenic Injury—Bone Loss Assessment	-	-	-	-	-	X	-
272	Inflammatory Bowel Disease (IBD): Preventive Care: Influenza Immunization	55.67%	29.18%	-	-	-	X	-
273	Inflammatory Bowel Disease (IBD): Preventive Care: Pneumococcal Immunization	26.06%	17.90%	-	-	-	X	-
274	Inflammatory Bowel Disease (IBD): Testing for Latent Tuberculosis (TB) Before Initiating Anti-TNF (Tumor Necrosis Factor) Therapy	94.77%	19.19%	-	-	-	X	-
275	Inflammatory Bowel Disease (IBD): Assessment of Hepatitis B Virus (HBV) Status Before Initiating Anti-TNF (Tumor Necrosis Factor) Therapy	-	-	-	-	-	X	-
276	Sleep Apnea: Assessment of Sleep Symptoms	98.21%	7.78%	-	-	-	X	-
277	Sleep Apnea: Severity Assessment at Initial Diagnosis	97.16%	10.81%	-	-	-	X	-
278	Sleep Apnea: Positive Airway Pressure Therapy Prescribed	99.40%	2.50%	-	-	-	X	-
279	Sleep Apnea: Assessment of Adherence to Positive Airway Pressure Therapy	94.14%	15.78%	-	-	-	X	-
281	Dementia: Cognitive Assessment	94.66%	16.44%	-	-	-	X	-

2013 PQRS Measure Number and Measure Name		2013 Mean	2013 Standard Deviation	2013 Reporting Options				
				Claims	Registry	EHR	Measures Group	GPRO Web Interface
282	Dementia: Functional Status Assessment	95.09%	14.04%	-	-	-	X	-
283	Dementia: Neuropsychiatric Symptom Assessment	90.86%	21.05%	-	-	-	X	-
284	Dementia: Management of Neuropsychiatric Symptoms	91.40%	21.57%	-	-	-	X	-
285	Dementia: Screening for Depressive Symptoms	89.97%	20.92%	-	-	-	X	-
287	Dementia: Counseling Regarding Risks of Driving	87.42%	27.02%	-	-	-	X	-
288	Dementia: Caregiver Education and Support	88.38%	25.13%	-	-	-	X	-
289	Parkinson's Disease: Annual Parkinson's Disease Diagnosis Review	98.83%	5.52%	-	-	-	X	-
290	Parkinson's Disease: Psychiatric Disorders or Disturbances Assessment	88.41%	19.91%	-	-	-	X	-
291	Parkinson's Disease: Cognitive Impairment or Dysfunction Assessment	91.47%	15.90%	-	-	-	X	-
292	Parkinson's Disease: Querying about Sleep Disturbances	83.22%	24.97%	-	-	-	X	-
293	Parkinson's Disease: Rehabilitative Therapy Options	83.73%	25.24%	-	-	-	X	-
294	Parkinson's Disease: Parkinson's Disease Medical and Surgical Treatment Options Reviewed	96.86%	13.19%	-	-	-	X	-
295	Hypertension (HTN): Appropriate Use of Aspirin or Other Antithrombotic Therapy	74.62%	23.83%	-	-	-	X	-
296	Hypertension (HTN): Complete Lipid Profile	93.01%	13.89%	-	-	-	X	-
297	Hypertension (HTN): Urine Protein Test	77.71%	26.28%	-	-	-	X	-
298	Hypertension (HTN): Annual Serum Creatinine Test	94.80%	11.98%	-	-	-	X	-
299	Hypertension (HTN): Diabetes Mellitus Screening Test	93.14%	16.10%	-	-	-	X	-
300	Hypertension (HTN): Blood Pressure Control	80.57%	18.21%	-	-	-	X	-
301	Hypertension (HTN): Low Density Lipoprotein (LDL-C) Control	79.84%	18.74%	-	-	-	X	-
302	Hypertension (HTN): Dietary and Physical Activity Modifications Appropriately Prescribed	83.80%	24.53%	-	-	-	X	-

2013 PQRS Measure Number and Measure Name		2013 Mean	2013 Standard Deviation	2013 Reporting Options				
				Claims	Registry	EHR	Measures Group	GPRO Web Interface
303	Cataracts: Improvement in Patient's Visual Function within 90 Days Following Cataract Surgery	91.53%	13.87%	-	X	-	X	-
305	Initiation and Engagement of Alcohol and Other Drug Dependence Treatment: (a) Initiation, (b) Engagement	-	-	-	-	X	-	-
309	Cervical Cancer Screening	35.42%	26.71%	-	-	X	-	-
311	Use of Appropriate Medications for Asthma	80.59%	14.36%	-	-	X	-	-
313	Diabetes Mellitus (DM): Hemoglobin A1c Control (< 8%)	66.12%	10.35%	-	-	X	-	-
316	Preventive Care and Screening: Cholesterol—Fasting Low Density Lipoprotein (LDL) Test Performed AND Risk-Stratified Fasting LDL	57.65%	27.07%	-	-	X	-	-
325	Adult Major Depressive Disorder (MDD): Coordination of Care of Patients with Specific Comorbid Conditions	-	-	-	X	-	-	-
327	Pediatric Kidney Disease: Adequacy of Volume Management	-	-	X	X	-	-	-
328*	Pediatric Kidney Disease: End Stage Renal Disease (ESRD) Patients Receiving Dialysis: Hemoglobin Level < 10 g/dL	-	-	X	X	-	-	-
Composite Measures								
-	Diabetes Mellitus (DM): Composite (All or Nothing Scoring)	25.20%	12.24%	-	-	-	-	X
(GPRO DM-13)	Diabetes Mellitus (DM): High Blood Pressure Control	70.68%	9.10%	-	-	-	-	X
(GPRO DM-14)	Diabetes Mellitus (DM): Low Density Lipoprotein (LDL-C) Control	57.17%	10.32%	-	-	-	-	X
(GPRO DM-15)	Diabetes Mellitus (DM): Hemoglobin A1c Control (< 8%)	70.54%	10.63%	-	-	-	-	X
(GPRO DM-16)	Diabetes Mellitus (DM): Daily Aspirin or Antiplatelet Medication Use for Patients with Diabetes and Ischemic Vascular Disease (IVD)	80.21%	15.26%	-	-	-	-	X
(GPRO DM-17)	Diabetes Mellitus (DM): Tobacco Non-Use	71.00%	23.68%	-	-	-	-	X

2013 PQRS Measure Number and Measure Name		2013 Mean	2013 Standard Deviation	2013 Reporting Options				
				Claims	Registry	EHR	Measures Group	GPRO Web Interface
-	Coronary Artery Disease (CAD): Composite (All or Nothing Scoring)	68.09%	14.47%	-	-	-	-	X
Patient and Family Engagement								
50	Urinary Incontinence: Plan of Care for Urinary Incontinence in Women Aged 65 Years and Older	94.09%	17.30%	X	X	-	-	-
109	Osteoarthritis (OA): Function and Pain Assessment	82.99%	29.81%	X	X	-	-	-
143	Oncology: Medical and Radiation—Pain Intensity Quantified	89.48%	19.58%	-	X	-	X	-
144	Oncology: Medical and Radiation—Plan of Care for Pain	86.23%	19.78%	-	X	-	X	-
304	Cataracts: Patient Satisfaction within 90 Days Following Cataract Surgery	98.94%	2.26%	-	X	-	X	-
Population/Public Health								
110 (GPRO PREV-7)	Preventive Care and Screening: Influenza Immunization	40.89%	27.69%	X	X	X	X	X
128 (GPRO PREV-9)	Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up	54.58%	23.30%	X	X	X	X	X
131	Pain Assessment and Follow-Up	93.70%	17.81%	X	X	-	-	-
134 (GPRO PREV-12)	Preventive Care and Screening: Screening for Clinical Depression and Follow-Up Plan	46.27%	36.01%	X	X	-	-	X
173	Preventive Care and Screening: Unhealthy Alcohol Use—Screening	54.08%	41.76%	X	X	X	X	-
183	Hepatitis C: Hepatitis A Vaccination in Patients with Hepatitis C Virus (HCV)	57.06%	31.80%	X	X	-	X	-
184	Hepatitis C: Hepatitis B Vaccination in Patients with Hepatitis C Virus (HCV)	56.76%	31.51%	X	X	-	X	-

2013 PQRS Measure Number and Measure Name		2013 Mean	2013 Standard Deviation	2013 Reporting Options				
				Claims	Registry	EHR	Measures Group	GPRO Web Interface
226 (GPRO PREV-10)	Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention	83.11%	24.97%	X	X	X	X	X
239	Weight Assessment and Counseling for Children and Adolescents	-	-	-	-	X	-	-
240	Childhood Immunization Status	-	-	-	-	X	-	-
306	Prenatal Care: Screening for Human Immunodeficiency Virus (HIV)	-	-	-	-	X	-	-
308	Smoking and Tobacco Use Cessation, Medical Assistance: a. Advising Smokers and Tobacco Users to Quit, b. Discussing Smoking and Tobacco Use Cessation Medications, c. Discussing Smoking and Tobacco Use Cessation Strategies	6.36%	7.78%	-	-	X	-	-
310	Chlamydia Screening for Women	-	-	-	-	X	-	-
317 (GPRO PREV-11)	Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up Documented	62.27%	29.98%	X	X	X	X	X
Patient Safety								
20	Perioperative Care: Timing of Prophylactic Parenteral Antibiotic— Ordering Physician	97.01%	11.10%	X	X	-	X	-
21	Perioperative Care: Selection of Prophylactic Antibiotic—First OR Second Generation Cephalosporin	93.61%	16.82%	X	X	-	X	-
22	Perioperative Care: Discontinuation of Prophylactic Parenteral Antibiotics (Non-Cardiac Procedures)	96.33%	13.40%	X	X	-	X	-
23	Perioperative Care: Venous Thromboembolism (VTE) Prophylaxis (When Indicated in ALL Patients)	96.52%	13.84%	X	X	-	X	-
30	Perioperative Care: Timely Administration of Prophylactic Parenteral Antibiotics	95.13%	10.41%	X	X	-	-	-
45	Perioperative Care: Discontinuation of Prophylactic Parenteral Antibiotics (Cardiac Procedures)	99.60%	2.52%	X	X	-	-	-

2013 PQRS Measure Number and Measure Name	2013 Mean	2013 Standard Deviation	2013 Reporting Options					
			Claims	Registry	EHR	Measures Group	GPRO Web Interface	
46 (GPRO CARE-1)	Medication Reconciliation: Reconciliation After Discharge from an Inpatient Facility	81.63%	22.59%	X	X	-	-	X
76	Prevention of Catheter-Related Bloodstream Infections (CRBSI): Central Venous Catheter (CVC) Insertion Protocol	84.42%	25.31%	X	X	-	-	-
130	Documentation of Current Medications in the Medical Record	87.36%	22.21%	X	X	-	X	-
145	Radiology: Exposure Time Reported for Procedures Using Fluoroscopy	74.20%	27.36%	X	X	-	-	-
154	Falls: Risk Assessment	73.21%	38.45%	X	X	-	-	-
156	Oncology: Radiation Dose Limits to Normal Tissues	98.96%	4.20%	X	X	-	-	-
157	Thoracic Surgery: Recording of Clinical Stage Prior to Lung Cancer or Esophageal Cancer Resection	-	-	X	X	-	-	-
181	Elder Maltreatment Screen and Follow-Up Plan	96.58%	14.89%	X	X	-	-	-
192*	Cataracts: Complications Within 30 Days Following Cataract Surgery Requiring Additional Surgical Procedures	10.52%	29.49%	-	X	-	X	-
193	Perioperative Temperature Management	93.50%	10.13%	X	X	-	-	-
234	Thoracic Surgery: Pulmonary Function Tests Before Major Anatomic Lung Resection (Pneumonectomy, Lobectomy or Formal Segmentectomy)	-	-	-	X	-	-	-
238*	Drugs to Be Avoided in the Elderly	16.05%	8.86%	-	-	X	-	-
262	Image Confirmation of Successful Excision of Image-Localized Breast Lesion	99.55%	1.47%	X	X	-	-	-
286	Dementia: Counseling Regarding Safety Concerns	91.06%	21.13%	-	-	-	X	-
307	Prenatal Care: Anti-D Immune Globulin	-	-	-	-	X	-	-
318 (GPRO CARE-2)	Falls: Screening for Future Fall Risk	42.09%	25.62%	-	-	-	-	X
326	Atrial Fibrillation and Atrial Flutter: Chronic Anticoagulation Therapy	96.76%	11.46%	X	X	-	-	-

2013 PQRS Measure Number and Measure Name		2013 Mean	2013 Standard Deviation	2013 Reporting Options				
				Claims	Registry	EHR	Measures Group	GPRO Web Interface
Care Coordination								
24	Osteoporosis: Communication with the Physician Managing Ongoing Care Post-Fracture of Hip, Spine or Distal Radius for Men and Women Aged 50 Years and Older	78.05%	30.27%	X	X	-	-	-
47	Advance Care Plan	53.42%	33.40%	X	X	X	-	-
81	Adult Kidney Disease: Hemodialysis Adequacy: Solute	-	-	-	X	-	-	-
82	Adult Kidney Disease: Peritoneal Dialysis Adequacy: Solute	-	-	-	X	-	-	-
93	Acute Otitis Externa (AOE): Systemic Antimicrobial Therapy—Avoidance of Inappropriate Use	94.95%	11.83%	X	X	-	-	-
138	Melanoma: Coordination of Care	89.33%	22.85%	-	X	-	-	-
141	Primary Open-Angle Glaucoma (POAG): Reduction of Intraocular Pressure (IOP) by 15% OR Documentation of a Plan of Care	99.14%	4.87%	X	X	-	-	-
147	Nuclear Medicine: Correlation with Existing Imaging Studies for All Patients Undergoing Bone Scintigraphy	69.59%	24.21%	X	X	-	-	-
155	Falls: Plan of Care	74.52%	38.15%	X	X	-	-	-
180	Rheumatoid Arthritis (RA): Glucocorticoid Management	99.32%	4.02%	X	X	-	X	-
182	Functional Outcome Assessment	91.42%	21.02%	X	X	-	-	-
185	Endoscopy & Polyp Surveillance: Colonoscopy Interval for Patients with a History of Adenomatous Polyps—Avoidance of Inappropriate Use	97.69%	5.14%	X	X	-	-	-
188	Referral for Otologic Evaluation for Patients with Congenital or Traumatic Deformity of the Ear	-	-	X	X	-	-	-
217	Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Knee Impairments	82.42%	13.58%	-	X	-	-	-
218	Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Hip Impairments	79.52%	12.56%	-	X	-	-	-
219	Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Lower Leg, Foot or Ankle Impairments	-	-	-	X	-	-	-

2013 PQRS Measure Number and Measure Name		2013 Mean	2013 Standard Deviation	2013 Reporting Options				
				Claims	Registry	EHR	Measures Group	GPRO Web Interface
220	Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Lumbar Spine Impairments	73.14%	16.45%	-	X	-	-	-
221	Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Shoulder Impairments	78.85%	12.62%	-	X	-	-	-
222	Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Elbow, Wrist or Hand Impairments	-	-	-	X	-	-	-
223	Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Neck, Cranium, Mandible, Thoracic Spine, Ribs or Other General Orthopedic Impairments	73.19%	13.27%	-	X	-	-	-
225	Radiology: Reminder System for Mammograms	88.63%	24.24%	X	X	-	-	-
256	Surveillance after Endovascular Abdominal Aortic Aneurysm Repair (EVAR)	-	-	-	X	-	-	-
258	Rate of Open Repair of Small or Moderate Non-Ruptured Abdominal Aortic Aneurysms (AAA) without Major Complications (Discharged to Home by Post-Operative Day #7)	-	-	-	X	-	-	-
259	Rate of Endovascular Aneurysm Repair (EVAR) of Small or Moderate Non-Ruptured Abdominal Aortic Aneurysms (AAA) without Major Complications (Discharged to Home by Post-Operative Day #2)	-	-	-	X	-	-	-
260	Rate of Carotid Endarterectomy (CEA) for Asymptomatic Patients without Major Complications (Discharged to Home by Post-Operative Day #2)	-	-	-	X	-	-	-
261	Referral to Otologic Evaluation for Patients with Acute or Chronic Dizziness	92.34%	23.88%	X	X	-	-	-
265	Biopsy Follow-Up	83.32%	25.26%	-	X	-	-	-
280	Dementia: Staging of Dementia	90.40%	22.76%	-	-	-	X	-
320	Endoscopy/Polyp Surveillance: Appropriate Follow-Up Interval for Normal Colonoscopy in Average Risk Patients	78.96%	19.84%	X	X	-	-	-

2013 PQRS Measure Number and Measure Name		2013 Mean	2013 Standard Deviation	2013 Reporting Options				
				Claims	Registry	EHR	Measures Group	GPRO Web Interface
321	Participation by a Hospital, Physician or Other Clinician in a Systematic Clinical Database Registry that Includes Consensus Endorsed Quality	99.99%	0.15%	X	X	-	-	-
Efficient Use of Health Care Resources								
65	Appropriate Treatment for Children with Upper Respiratory Infection (URI)	-	-	X	X	-	-	-
66	Appropriate Testing for Children with Pharyngitis	-	-	X	X	X	-	-
102	Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients	-	-	X	X	X	-	-
116	Antibiotic Treatment for Adults with Acute Bronchitis: Avoidance of Inappropriate Use	-	-	X	X	-	-	-
146*	Radiology: Inappropriate Use of "Probably Benign" Assessment Category in Mammography Screening	0.32%	1.12%	X	X	-	-	-
148	Back Pain: Initial Visit	91.57%	22.06%	-	-	-	X	-
224	Melanoma: Overutilization of Imaging Studies in Melanoma	99.47%	3.46%	-	X	-	-	-
312	Low Back Pain: Use of Imaging Studies	-	-	-	-	X	-	-
322*	Cardiac Stress Imaging Not Meeting Appropriate Use Criteria: Preoperative Evaluation in Low Risk Surgery Patients	-	-	-	X	-	-	-
323*	Cardiac Stress Imaging Not Meeting Appropriate Use Criteria: Routine Testing After Percutaneous Coronary Intervention (PCI)	-	-	-	X	-	-	-
324*	Cardiac Stress Imaging Not Meeting Appropriate Use Criteria: Testing in Asymptomatic, Low Risk Patients	-	-	-	X	-	-	-

Note: This table presents means, standard deviations, and reporting options for 2013 PQRS measures. Not all benchmarks will be applicable to 2014 performance, depending on whether a comparable measure exists in 2014. Benchmarks are not available for measures where fewer than twenty groups reported at least twenty cases.

* Lower performance rates on this measure indicate better performance

Consumer Assessment of Healthcare Providers and Systems (CAHPS) for PQRS Measures

PQRS Measure Name	2013 Mean	2013 Standard Deviation
Getting Timely Care, Appointments and Information	81.46	3.65
How Well Providers Communicate	93.14	1.38
Patient's Rating of Provider	92.12	1.39
Access to Specialists	84.92	2.26
Health Promotion & Education	58.34	3.87
Shared Decision Making	74.69	2.53
Care Coordination	87.99	1.84
Courteous and Helpful Office Staff	92.78	1.70
Helping You to Take Medication as Directed	75.85	1.98
Stewardship of Patient Resources	25.98	4.52
Between Visit Communication	58.28	7.65

Note: CAHPS for PQRS measures are scored on a 0 to 100 point scale. Data on the health and functional status measure, a descriptive measure of patient characteristics, is being provided to groups and solo practitioners for their information only. As this measure will not be used in the calculation of the VM, no benchmark is calculated.

Benchmarking and Measure Calculation Methodology

- Benchmark means were computed as the case-weighted average of 2013 performance rates computed across all medical group practices (identified by Tax Identification Number, or TIN) with at least twenty cases.
 - For each measure, each TIN's weight was the number of cases for the TIN divided by the total number of cases for the measure.
 - The case-weighted mean was computed by multiplying the performance rate for each TIN by its weight and then summing all terms.
 - For PQRS measures, performance rates for satisfactory reporters were combined across reporting options.
 - Benchmarks were not computed if fewer than twenty TINs reported at least twenty cases.
- Performance rates for the all cause readmission and ambulatory care sensitive condition measures were computed:
 - Using 2013 measure specifications. Narrative specifications can be found at <http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/PhysicianFeedbackProgram/2013-QRUR.html>.
 - For all TINs with at least one physician.
- PQRS performance rates reported by individual EPs were rolled up to the TIN level prior to computing benchmarks.
 - Only performance rates for EPs eligible for the 2013 PQRS incentive were included.
 - For a given measure, all available submission mechanisms were included.
 - If an EP within a TIN reported a performance rate for a measure under multiple mechanisms, then the mechanism associated with the best performance rate was selected.
 - For each TIN and measure, rates were rolled up to the TIN level as follows:
 - For each EP within the TIN, the performance rate was multiplied by the denominator cases. The TIN numerator was then calculated as the sum across all EPs within the TIN that reported the measure.
 - The TIN denominator was calculated as the sum of the denominator cases across all EPs within the TIN that reported the measure.
 - Each TIN's performance rate on the measure was calculated as the TIN numerator divided by the TIN denominator.